Bristol-Myers Squibb Company (NYSE:BMY) is considered one of the most undervalued low volatility stocks to buy now. On August 25, BMO Capital analyst Evan Seigerman maintained a Hold rating on BMY with a price target of $47.00. The analyst supported the rating with the present performance and future expectations for Bristol-Myers Squibb Company’s product, Cobenfy.

Seigerman noted that while Cobenfy showed solid prescription growth, it did not indicate a significant market breakthrough. Despite an increase in weekly and monthly prescriptions, the analyst expects the numbers to fall short of consensus revenue expectations for fiscal Q3 2025. Revised assumptions on inventory levels and discounts add uncertainty to revenue forecasts, supporting the Hold rating.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company specializing in advanced medicines for serious diseases across various therapeutic classes. While BMY presents investment potential, some AI stocks may offer greater upside potential and less downside risk. For an undervalued AI stock primed to benefit from tariffs and onshoring trends, check out Insider Monkey’s free report on the best short-term AI stock.

Read more at Yahoo Finance: BMO Capital Maintains a Hold on Bristol-Myers Squibb (BMY)